Jan Marquard
Ingelheim Am Rhein, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023.
Journal: Kidney international
Published: April 23, 2025
Impact of Empagliflozin on Glomerular Hyperfiltration and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of DINAMO.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: January 29, 2025
Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10-17 years with type 2 diabetes mellitus.
Journal: British journal of clinical pharmacology
Published: July 05, 2024
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial.
Journal: Therapeutic innovation & regulatory science
Published: May 14, 2024
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: October 26, 2022
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: September 18, 2021
Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop.
Journal: Clinical pharmacology and therapeutics
Published: November 06, 2019
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Journal: Diabetes, obesity & metabolism
Published: September 23, 2019
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Journal: Diabetes care
Published: March 19, 2019
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Journal: Diabetes care
Published: August 16, 2018
Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: March 26, 2018
Last Updated: 09/26/2026